血清γ-谷氨酰转移酶作为恩杂鲁胺治疗转移性去势抵抗性前列腺癌的预后生物标志物
Serum γ-Glutamyltransferase as a Prognostic Biomarker in Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide.
作者信息
Takemura Kosuke, Ito Masaya, Nakanishi Yasukazu, Kataoka Madoka, Sakamoto Kazumasa, Suzuki Hiroaki, Tobisu Ken-Ichi, Koga Fumitaka
机构信息
Department of Urology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan
Department of Urology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
出版信息
Anticancer Res. 2019 Oct;39(10):5773-5780. doi: 10.21873/anticanres.13780.
BACKGROUND/AIM: Serum γ-glutamyltransferase (GGT) is reportedly associated with survival and therapeutic response in various malignancies; however, as far as we are aware its impact on metastatic castration-resistant prostate cancer (mCRPC) has never been assessed.
PATIENTS AND METHODS
Fifty consecutive men with mCRPC receiving enzalutamide at a single cancer center were retrospectively evaluated. The primary endpoint was overall survival (OS) and the secondary endpoints were prostate-specific antigen (PSA) response, maximal PSA change, and PSA progression-free survival (PSA-PFS).
RESULTS
Multivariable analysis demonstrated that elevation of GGT (≥40 U/l) was significantly and independently associated with shorter OS (hazard ratio(HR)=3.61; p=0.004), as were lower hemoglobin (HR=6.04; p<0.001) and higher PSA (HR=4.38; p=0.009). Elevated GGT was also associated with poorer PSA response, maximal PSA change, and shorter PSA-PFS.
CONCLUSION
Elevated GGT was an adverse prognostic indicator in men with mCRPC receiving enzalutamide. External validations would improve the generality of our findings.
背景/目的：据报道，血清γ-谷氨酰转移酶（GGT）与多种恶性肿瘤的生存率及治疗反应相关；然而，据我们所知，其对转移性去势抵抗性前列腺癌（mCRPC）的影响尚未得到评估。
患者与方法
对在单一癌症中心接受恩杂鲁胺治疗的50例连续的mCRPC男性患者进行回顾性评估。主要终点为总生存期（OS），次要终点为前列腺特异性抗原（PSA）反应、PSA最大变化及PSA无进展生存期（PSA-PFS）。
结果
多变量分析表明，GGT升高（≥40 U/l）与较短的OS显著且独立相关（风险比[HR]=3.61；p=0.004），血红蛋白降低（HR=6.04；p<0.001）及PSA升高（HR=4.38；p=0.009）也与之相关。GGT升高还与较差的PSA反应、PSA最大变化及较短的PSA-PFS相关。
结论
GGT升高是接受恩杂鲁胺治疗的mCRPC男性患者的不良预后指标。外部验证将提高我们研究结果的普遍性。
Zotero 插件